Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 2/2024

26-02-2024 | Hepatitis B | Review

Management of Hepatitis B in Pregnancy

Authors: Jeanette Rios, Lital Aliasi-Sinai, Natalia Schmidt, Tatyana Kushner

Published in: Current Hepatology Reports | Issue 2/2024

Login to get access

Abstract

Purpose of Review

In 2016, WHO sets a target to eliminate viral hepatitis as a public health threat by 2030, with significant emphasis placed on reducing MTCT of HBV, which is the leading cause of CHB worldwide. In this review, we discuss the most recent recommendations in the literature on the management of HBV in pregnancy, including treatment considerations during pregnancy and recommendations for infant management, to reduce the MTCT of HBV.

Recent Findings

Recent research advancements have focused on further unraveling the safety and efficacy of treatment options during pregnancy, developing more accessible postnatal immunoprophylaxis regimens, and exploring theoretical models for HBV treatment during pregnancy aimed at preventing MTCT.

Summary

Despite considerable public health efforts, HBV remains a significant global health concern. Effective collaboration among clinicians is essential for appropriate screening, assessment, treatment during and after pregnancy, and proper follow-up, in order to reduce the MTCT of HBV and optimize maternal health outcomes.
Literature
1.
Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for impact. World Health Organization; 2021.
2.
World Health Organization. Global Hepatitis Report 2017. World Health Organization; Report No.: Licence: CC BY-NC-SA 3.0 IGO.
3.
Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis. 2016;20:607–28.PubMedPubMedCentralCrossRef
4.
Kushner T, Chen Z, Tressler S, Kaufman H, Feinberg J, Terrault NA. Trends in hepatitis B infection and immunity among women of childbearing age in the United States. Clin Infect Dis. 2020;71:586–92.PubMedCrossRef
5.
6.
Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977;105:94–8.PubMedCrossRef
7.
Veronese P, Dodi I, Esposito S, Indolfi G. Prevention of vertical transmission of hepatitis B virus infection. World J Gastroenterol. 2021;27:4182–93.PubMedPubMedCentralCrossRef
8.
World Health Organization. Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection: Mar-15. World Health Organization; 2015.
9.
10.
11.
Chen B, Wang Y, Lange M, Kushner T. Hepatitis C is associated with more adverse pregnancy outcomes than hepatitis B: a 7-year national inpatient sample study. Hepatol Commun. 2022;6:2465–73.PubMedPubMedCentralCrossRef
12.
Huang Q-T, Wei S-S, Zhong M, Hang L-L, Xu Y-Y, Cai G-X, et al. Chronic hepatitis B infection and risk of preterm labor: a meta-analysis of observational studies. J Clin Virol. 2014;61:3–8.PubMedCrossRef
13.
Zhang Y, Chen J, Liao T, Chen S, Yan J, Lin X. Correction to: Maternal HBsAg carriers and pregnancy outcomes: a retrospective cohort analysis of 85,190 pregnancies. BMC Pregnancy Childbirth. 2021;21:131.PubMedPubMedCentralCrossRef
14.
Jiang R, Wang T, Yao Y, Zhou F, Huang X. Hepatitis B infection and intrahepatic cholestasis of pregnancy: a systematic review and meta-analysis. Medicine. 2020;99:e21416.PubMedPubMedCentralCrossRef
15.
Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J Hepatol. 2005;43:771–5.PubMedCrossRef
16.
Sirilert S, Traisrisilp K, Sirivatanapa P, Tongsong T. Pregnancy outcomes among chronic carriers of hepatitis B virus. Int J Gynaecol Obstet. 2014;126:106–10.PubMedCrossRef
17.
Cui A-M, Cheng X-Y, Shao J-G, Li H-B, Wang X-L, Shen Y, et al. Maternal hepatitis B virus carrier status and pregnancy outcomes: a prospective cohort study. BMC Pregnancy Childbirth. 2016;16:87.PubMedPubMedCentralCrossRef
18.
Kong D, Liu H, Wei S, Wang Y, Hu A, Han W, et al. A meta-analysis of the association between gestational diabetes mellitus and chronic hepatitis B infection during pregnancy. BMC Res Notes. 2014;7:139.PubMedPubMedCentralCrossRef
19.
Huang QT, Chen JH, Zhong M, Xu YY, Cai CX, Wei SS, et al. The risk of placental abruption and placenta previa in pregnant women with chronic hepatitis B viral infection: a systematic review and meta-analysis. Placenta. 2014;35:539–45.PubMedCrossRef
20.
Kushner T, Shaw PA, Kalra A, Magaldi L, Monpara P, Bedi G, et al. Incidence, determinants and outcomes of pregnancy-associated hepatitis B flares: a regional hospital-based cohort study. Liver Int. 2018;38:813–20.PubMedCrossRef
21.
Chang CY, Aziz N, Poongkunran M, Javaid A, Trinh HN, Lau D, et al. Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B. Am J Gastroenterol. 2016;111:1410–5.PubMedCrossRef
22.
ter Borg MJ, Leemans WF, de Man RA, Janssen HLA. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat. 2008;15:37–41.PubMedCrossRef
23.
Giles M, Visvanathan K, Lewin S, Bowden S, Locarnini S, Spelman T, et al. Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B. Gut. 2015;64:1810–5.PubMedCrossRef
24.
Liu J, Wang J, Qi C, Cao F, Tian Z, Guo D, et al. Baseline hepatitis B virus titer predicts initial postpartum hepatic flare: a multicenter prospective study. J Clin Gastroenterol. 2018;52:902–7.PubMedCrossRef
25.
Nguyen V, Tan PK, Greenup A-J, Glass A, Davison S, Samarasinghe D, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment Pharmacol Ther. 2014;39:1225–34.PubMedCrossRef
26.
US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019;322:349–54.CrossRef
27.
Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.PubMedCrossRef
28.
Dionne-Odom J, Tita ATN, Silverman NS. #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol. 2016;214:6–14.PubMedCrossRef
29.
Han Z, Zhang Y, Zhou J, Wang Q, Huang Y, Hou H. Risk of mother-to-child transmission of hepatitis B virus after fetal blood sampling: a report of six cases. BMC Infect Dis. 2021;21:716.PubMedPubMedCentralCrossRef
30.
Han Z, Zhang Y, Bai X, Yin Y, Xu C, Hou H. Mother-to-child transmission of hepatitis B virus after amniocentesis: a retrospective matched cohort study. Prenat Diagn. 2019;39:431–40.PubMedCrossRef
31.
Du X, Zhang L, Liu Z, Qian Y, Zhang X, Hu T, et al. Risk of mother-to-child transmission after amniocentesis in pregnant women with hepatitis B virus: a retrospective cohort study. Am J Obstet Gynecol. 2024;230:249.e1–8.PubMedCrossRef
32.
Kushner T, Sarkar M. Chronic hepatitis B in pregnancy. Clin Liver Dis. 2018;12:24–8.CrossRef
33.
34.
Weng MK, Doshani M, Khan MA, Frey S, Ault K, Moore KL, et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:477–83.PubMedPubMedCentralCrossRef
35.
Gupta I, Ratho RK. Immunogenicity and safety of two schedules of Hepatitis B vaccination during pregnancy. J Obstet Gynaecol Res. 2003;29:84–6.PubMedCrossRef
36.
37.
Kushner T, Huang V, Janssen R. Safety and immunogenicity of HepB-CpG in women with documented pregnancies post-vaccination: a retrospective chart review. Vaccine. 2022;40:2899–903.PubMedCrossRef
38.
World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus (HBV): guidelines on antiviral prophylaxis in pregnancy. World Health Organization; 2020.
39.
Hou J, Cui F, Ding Y, Dou X, Duan Z, Han G, et al. Management algorithm for interrupting mother-to-child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2019;17:1929–36.e1.PubMedCrossRef
40.
41.
42.
Pan CQ, Duan Z-P, Bhamidimarri KR, Zou H-B, Liang X-F, Li J, et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2012;10:452–9.PubMedCrossRef
43.•
Nayagam S, de Villiers MJ, Shimakawa Y, Lemoine M, Thursz MR, Walsh N, et al. Impact and cost-effectiveness of hepatitis B virus prophylaxis in pregnancy: a dynamic simulation modelling study. Lancet Gastroenterol Hepatol. 2023;8:635–45. Important modeling study highlighting the potential impact of universal peripartum prophylaxis and describing current barriers to implementation.PubMedCrossRef
44.
45.
46.
Gao F, Zhang W-T, Lin Y-Y, Wang W-M, Xu N, Bai G-Q. Early start of tenofovir treatment achieves better viral suppression in pregnant women with a high HBV viral load: a real-world prospective study. Infect Drug Resist. 2019;12:3475–84.PubMedPubMedCentralCrossRef
47.
Wu Y, Liu J, Feng Y, Fu S, Ji F, Ge L, et al. Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: systematic review and network meta-analysis. Hepatol Int. 2020;14:180–9.PubMedCrossRef
48.
Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, et al. Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411–29.PubMedPubMedCentralCrossRef
49.
Li M, Sun F, Bi X, Lin Y, Yang L, Jiang T, et al. Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection. Hepatol Int. 2023;17:42–51.PubMedCrossRef
50.
Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel SM, Ward JW. Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57(RR-8):1–20.
51.
Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55:1–33. quiz CE1–4.PubMed
52.••
Segeral O, Dim B, Durier C, Nhoueng S, Chhim K, Sovann S, et al. Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial. Lancet Infect Dis. 2022;22:1181–90. Important phase 4 trial that focuses on prevention of vertical transmission of HBV without HBIg, which has important implications in developing countries that do not have access to HBIg.PubMedCrossRef
53.
54.
Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374:2324–34.PubMedCrossRef
55.
Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014; [Internet]. Available from: https://​doi.​org/​10.​1002/​hep.​27034.
56.
Siberry GK, Jacobson DL, Kalkwarf HJ, Wu JW, DiMeglio LA, Yogev R, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis. 2015;61:996–1003.PubMedPubMedCentralCrossRef
57.
Jacobson DL, Patel K, Williams PL, Geffner ME, Siberry GK, DiMeglio LA, et al. Growth at 2 years of age in HIV-exposed uninfected children in the United States by trimester of maternal antiretroviral initiation. Pediatr Infect Dis J. 2017;36:189–97.PubMedPubMedCentralCrossRef
58.
59.
Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496–505.PubMedCrossRef
60.
Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.PubMedPubMedCentral
61.
Baltrusaitis K, Makanani B, Tierney C, Fowler MG, Moodley D, Theron G, et al. Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial. BMC Infect Dis. 2022;22:634.PubMedPubMedCentralCrossRef
62.
Li Z, Xie B, Yi N, Cai H, Yi W, Gao X. Efficacy and safety of tenofovir disoproxil fumarate or telbivudine used throughout pregnancy for the prevention of mother-to-child transmission of hepatitis B virus: a cohort study. Eur J Obstet Gynecol Reprod Biol. 2022;276:102–6.PubMedCrossRef
63.••
Wang M, Ran R, Zhu Y, Zhang H. Comparison of tenofovir disoproxil fumarate and telbivudine in preventing hepatitis B transmission in mothers with high viral load. Int J Gynaecol Obstet. 2023;160:646–52. Important prospective cohort study demonstrating TDF’s ability to more effectively reduce viral load and have fewer liver abnormalities compared to telbivudine.PubMedCrossRef
64.
Han G, Zhou G, Sun T, Luo X, Xu J, Chen C, et al. Tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus: a multi-center, prospective study. J Matern Fetal Neonatal Med. 2022;35:10551–8.PubMedCrossRef
65.••
Zeng Q-L, Zhang H-X, Zhang J-Y, Huang S, Li W-Z, Li G-M, et al. Tenofovir alafenamide for pregnant Chinese women with active chronic hepatitis B: a multicenter prospective study. Clin Gastroenterol Hepatol. 2022;20:2826–37.e9. Important prospective cohort study on pregnant women with CHB showing similar effectiveness and safety with TAF therapy compared to TDF.PubMedCrossRef
66.
Thimm MA, Livingston A, Ramroop R, Eke AC. Pregnancy outcomes in pregnant women with HIV on tenofovir disoproxil fumarate (TDF) compared to tenofovir alafenamide (TAF). J AIDS HIV Treat. 2022;4:6–13.PubMedPubMedCentral
67.
Zeng Q-L, Yu Z-J, Ji F, Li G-M, Zhang G-F, Xu J-H, et al. Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective, observational study. Clin Infect Dis. 2021;73:e3324–32.PubMedCrossRef
68.
Li B, Liu Z, Liu X, Liu D, Duan M, Gu Y, et al. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load. Hepatol Int. 2021;15:1103–8.PubMedCrossRef
69.
70.
71.
72.
Machaira M, Papaevangelou V, Vouloumanou EK, Tansarli GS, Falagas ME. Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg− mothers: a systematic review and meta-analysis. J Antimicrob Chemother. 2014;70:396–404.PubMedCrossRef
73.
Lu Y, Liang X-F, Wang F-Z, Yan L, Li R-C, Li Y-P, et al. Hepatitis B vaccine alone may be enough for preventing hepatitis B virus transmission in neonates of HBsAg (+)/HBeAg (-) mothers. Vaccine. 2017;35:40–5.PubMedCrossRef
74.
Peng S, Wan Z, Liu T, Li X, Du Y. Cesarean section reduces the risk of early mother-to-child transmission of hepatitis B virus. Dig Liver Dis. 2018;50:1076–80.PubMedCrossRef
75.
Deng TK, Yang P, Liu X, Wang D, Luo H, Zhou J, et al. Influence of different delivery modes and HBV DNA titers on mother-to-child transmission of hepatitis B. Clin Res Hepatol Gastroenterol. 2021;45:101542.PubMedCrossRef
76.
Yang M, Qin Q, Fang Q, Jiang L, Nie S. Cesarean section to prevent mother-to-child transmission of hepatitis B virus in China: a meta-analysis. BMC Pregnancy Childbirth. 2017;17:303.PubMedPubMedCentralCrossRef
77.
78.
Shi Z, Yang Y, Wang H, Ma L, Schreiber A, Li X, et al. Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. Arch Pediatr Adolesc Med. 2011;165:837–46.PubMedCrossRef
79.
Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol. 2002;99:1049–52.PubMed
80.
Benaboud S, Pruvost A, Coffie PA, Ekouévi DK, Urien S, Arrivé E, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d’Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother. 2011;55:1315–7.PubMedCrossRef
81.
Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr. 2014;65:33–41.PubMedPubMedCentralCrossRef
82.
Waitt C, Olagunju A, Nakalema S, Kyohaire I, Owen A, Lamorde M, et al. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. J Antimicrob Chemother. 2018;73:1013–9.PubMedPubMedCentralCrossRef
83.
Van Rompay KKA, Hamilton M, Kearney B, Bischofberger N. Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques. Antimicrob Agents Chemother. 2005;49:2093–4.PubMedPubMedCentralCrossRef
84.
Ehrhardt S, Xie C, Guo N, Nelson K, Thio CL. Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clin Infect Dis. 2015;60:275–8.PubMedCrossRef
85.
Liu Z, Chen Z, Cui F, Ding Y, Gao Y, Han G, et al. Management algorithm for prevention of mother-to-child transmission of hepatitis B virus (2022). J Clin Transl Hepatol. 2022;10:1004–10.PubMedPubMedCentralCrossRef
86.•
Erturk US, Mete B, Ozaras R, Saltoglu N, Balkan II, Mert A, et al. Plasma and breast milk pharmacokinetics of tenofovir disoproxil fumarate in nursing mother with chronic hepatitis B-infant pairs. Antimicrob Agents Chemother. 2021;65:e0111021. This paper examines the distribution of TDF in both plasma and breast milk, and provides new evidence for the safety of infants exposed to breast milk containing TDF.PubMedCrossRef
Metadata
Title
Management of Hepatitis B in Pregnancy
Authors
Jeanette Rios
Lital Aliasi-Sinai
Natalia Schmidt
Tatyana Kushner
Publication date
26-02-2024
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 2/2024
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-024-00659-2

Other articles of this Issue 2/2024

Current Hepatology Reports 2/2024 Go to the issue

Review

Treatment of Gastric Varices

Review

Acute Kidney Injury in Acute on Chronic Liver Failure Versus Decompensated Cirrhosis—What Is the Difference?

Review

Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B

Review

When to Stop Antiviral Therapy in HBeAg-Negative Patients with Chronic Hepatitis B?

Review

Hepatitis B Virus Elimination Strategies

Review

A Review of Hepatitis B Reactivation Risk on Immunosuppressants with a Focus on Newer Immunomodulators
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits